MannKind (MNKD) Expected to Announce Earnings on Wednesday

MannKind (NASDAQ:MNKD) is anticipated to announce its Q1 2026 results before the market opens on Wednesday, May 6th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $105.3810 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 4:30 PM ET.

MannKind (NASDAQ:MNKD) last announced its earnings results on Thursday, February 26th. The biopharmaceutical company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.04). The company had revenue of $111.96 million for the quarter, compared to analyst estimates of $99.85 million. MannKind had a negative return on equity of 11.21% and a net margin of 1.68%.The business’s quarterly revenue was up 45.8% on a year-over-year basis. During the same quarter last year, the business posted $0.03 earnings per share. On average, analysts expect MannKind to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MannKind Stock Down 1.9%

MNKD traded down $0.06 during trading on Monday, hitting $2.79. The company had a trading volume of 1,469,216 shares, compared to its average volume of 5,235,377. The firm’s 50-day moving average price is $2.86 and its 200 day moving average price is $4.63. The company has a market capitalization of $860.01 million, a PE ratio of 139.32 and a beta of 1.04. MannKind has a one year low of $2.23 and a one year high of $6.51.

Insider Buying and Selling at MannKind

In related news, CEO Michael Castagna bought 100,000 shares of the stock in a transaction that occurred on Tuesday, March 10th. The shares were acquired at an average price of $2.59 per share, with a total value of $259,000.00. Following the completion of the transaction, the chief executive officer owned 2,575,911 shares in the company, valued at $6,671,609.49. The trade was a 4.04% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 2.60% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Franklin Resources Inc. boosted its holdings in shares of MannKind by 1.4% in the 3rd quarter. Franklin Resources Inc. now owns 162,217 shares of the biopharmaceutical company’s stock valued at $871,000 after buying an additional 2,201 shares during the last quarter. Mariner LLC increased its holdings in MannKind by 1.3% during the fourth quarter. Mariner LLC now owns 209,479 shares of the biopharmaceutical company’s stock worth $1,188,000 after buying an additional 2,777 shares during the last quarter. Caitong International Asset Management Co. Ltd raised its position in MannKind by 108.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,636 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 2,927 shares in the last quarter. Royal Bank of Canada raised its position in MannKind by 2.1% during the fourth quarter. Royal Bank of Canada now owns 206,612 shares of the biopharmaceutical company’s stock worth $1,170,000 after acquiring an additional 4,200 shares in the last quarter. Finally, Alliancebernstein L.P. lifted its stake in MannKind by 1.7% in the third quarter. Alliancebernstein L.P. now owns 279,091 shares of the biopharmaceutical company’s stock valued at $1,499,000 after acquiring an additional 4,541 shares during the last quarter. 49.55% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. Weiss Ratings cut MannKind from a “hold (c)” rating to a “sell (d+)” rating in a research report on Monday, March 2nd. Mizuho dropped their target price on MannKind from $10.00 to $8.00 and set an “outperform” rating on the stock in a research report on Monday, April 13th. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $3.50 price target (down from $7.50) on shares of MannKind in a research report on Friday, February 27th. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price target on shares of MannKind in a research note on Wednesday, February 25th. Finally, Wedbush lowered their price objective on shares of MannKind from $10.00 to $8.00 and set an “outperform” rating on the stock in a report on Thursday, March 5th. Seven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, MannKind has a consensus rating of “Moderate Buy” and a consensus target price of $8.69.

MannKind Company Profile

MannKind Corporation is a biopharmaceutical company specialized in the development and commercialization of inhaled therapeutic products. The company’s core business revolves around its proprietary Technosphere® drug?delivery platform, which is designed to enable rapid absorption of small?molecule drugs through pulmonary administration. MannKind’s lead product, Afrezza®, is an inhaled insulin therapy intended for adults with type 1 and type 2 diabetes, offering users a rapid?acting alternative to traditional injectable insulins.

Afrezza received U.S.